Holyject Pharmaceutical Technology

Holyject Pharmaceutical Technology is a clinical-stage biotechnology company specializing in the development of long-acting injectable formulations and advanced drug delivery systems. The company leverages proprietary technology platforms, including lipid-based nanoparticles and hydrogel systems, to improve the pharmacokinetic profiles of existing and novel therapeutics. Their primary focus areas include metabolic diseases, ophthalmology, and pain management, with a goal of reducing dosing frequency and improving patient compliance. Holyject's pipeline features long-acting versions of GLP-1 receptor agonists and VEGF inhibitors designed for sustained release over weeks or months. Based in Wuhan, China, the company integrates research, development, and pilot manufacturing to advance its portfolio toward commercialization.